Athira Pharma

Athira Pharma is a company listed under the stock ticker ATHA (US).

View the org chart displaying its 17 main executives

Most searched biographies at Athira Pharma

• Mark Litton, President and Chief Executive Officer
• Joseph Edelman, Director
• John Fluke, Director

Popular executive movements at Athira Pharma

• Javier San Martin has joined the company as Chief Medical Officer  (posted on April 16 2024).
• Hans Moebius, Chief Medical Officer, has left the company  (posted on April 16 2024).
• Josh Pan, Vice President, Corporate Development and External Affairs, has left the company  (posted on August 8 2023).

Create your alert
to follow the executive moves at Athira Pharma.

Athira Pharma has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Athira Pharma

• Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer | Athira Pharma
• Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease | Athira Pharma
• Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting | Athira Pharma
• Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference | Athira Pharma
• Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates | Athira Pharma
• Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease | Athira Pharma
• Athira Pharma to Participate in Upcoming October Conferences | Athira Pharma
• Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) | Athira Pharma
• Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates | Athira Pharma
• Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference | Athira Pharma
• View more press releases Close

Social media about Athira Pharma

• Athira Pharma on Wikipedia, Google News & Yahoo Finance
• Athira Pharma on LinkedIn, Twitter & YouTube

Contact by email its executives including Mark Litton

Call Athira Pharma at +1 98...

View the org chart

Register to receive your alert

Report an error